First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
